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Cardiac Sarcoidosis
Jhan Carlos Altamar and Miguel Jose Tejeda
Abstract
Sarcoidosis is a systemic disease of unknown origin characterized by the infiltra-
tion of non-necrotizing granulomas that can affect any organ. The presentation of 
cardiac involvement can range from slight infiltration to complete atrioventricular 
block, ventricular arrhythmia, or cardiac failure. The diagnosis requires a high 
index of suspicion; approach to treatment depends upon the presence, or absence, 
of extracardiac sarcoidosis; sometimes a biopsy of the myocardial tissue is the only 
way to obtain an accurate diagnosis. Nuclear magnetic resonance imaging is the 
imaging technique which can provide information useful in diagnosis of this condi-
tion. If there is active inflammation, the fundamental form of treatment is immu-
nosuppression therapy. Other concomitant treatments can be required such as the 
implantation of devices or modulation of arrhythmias. The prognosis is conditioned 
depending upon the extent of the disease and response to the therapy.
Keywords: sarcoidosis, nuclear magnetic resonance imaging, cardiac block,  
cardiac failure, arrhythmias, immunosuppression
1. Introduction
Sarcoidosis is a systemic disease of unknown origin characterized by infiltration 
of non-necrotizing granulomas. This disease can affect any organ, including the 
heart. The heart can be involved to a variable extent depending on the area studied 
[1]. The ACCES study reported about 95% of findings compatible with cardiac 
involvement [2]. Others report mainly pulmonary involvement. Studies in Japan 
report cardiac infiltration up to 25% in contrast with the European studies in which 
the prevalence ranges from 2 to 7% [3].
2. Epidemiology
Sarcoidosis has a worldwide prevalence of 4.7–64 per 100,000 individuals; the 
highest rates are found in Northern Europe and among Afro-Americans, predomi-
nantly in females [4]. The real prevalence of cardiac sarcoidosis is unknown. In 
some cases, it can be isolated without extracardiac involvement and in others can 
have no symptoms; the average age for this disease is 50 [5]. When the clinical 
behaviors of isolated cardiac sarcoidosis among the group of patients who also 
register extracardiac compromise are compared, it is found that patients who have 
the disease confined to the heart exhibit a higher prevalence of complete block 
of the right branch, delayed myocardial enhancement, and less elevation of the 
angiotensin-converting enzyme in serum, as they are clinically very similar in their 
presentation.
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3. Pathogenesis
This is a multisystem condition, of unknown etiology, which affects the lungs 
in most patients (90%) and usually involves the nodes and mediastinum. Cardiac 
involvement varies according to the population studied and can reach up to 25% 
[3]. The typical histological feature is the presence of non-necrotizing granuloma 
(see Figure 1) [6] with a central area rich in macrophages, epithelial cells, giant 
multinucleated cells, and T CD4-positive lymphocytes. In the periphery, there is an 
abundant population of T CD8 and CD4 lymphocytes, mast cells, and fibroblasts 
[7]. The origin of this condition is unknown, but one of the theories proposed is 
antigenic stimulation due to occupational and environmental exposure and infec-
tious agents such as mycobacteria [8].
4. Clinical manifestations
The manifestations of sarcoidosis vary and depend on the presence or absence 
of extracardiac compromise, extension, localization, and activity. The majority of 
heart signs and symptoms are subsequent to arrhythmia, anomalies in atrioven-
tricular conduction, and ventricular arrhythmia (including sudden death) as well as 
cardiac failure [4]. A less frequent clinical presentation is vasculitis of the coronary 
arteries. The clinical presentation ranges from palpitations, dyspnea, chest pain, to 
cardiorespiratory arrest.
Anomalies in atrioventricular conduction are the most frequent manifestation 
of cardiovascular compromise. They can have a variable clinical presentation that 
ranges from fixed prolongation of the PR interval (atrioventricular block degree 
1) to the presence of branch blocks and in more advanced cases complete atrio-
ventricular block. A prospective study identified that up to 34% of patients with 
atrioventricular block who were younger than 60 years old, without an apparently 
clear cause, were eventually diagnosed with sarcoidosis [9], the reason this entity 
should always be suspected in young patients who present with these alterations 
without an evident etiology.
The second form of presentation is ventricular arrhythmias which include the 
presence of premature ventricular complexes and ventricular tachycardia (sus-
tained and non-sustained), mostly subsequent to an increase in cardiac automatism 
or a reentrant mechanism around the scar caused by granulomas in the myocar-
dium. This type of compromise takes place in ~30% of patients [5]; even these 
arrhythmias can be the first manifestation of sarcoidosis [6].
Figure 1. 
Cardiac tissue biopsy. Fragments of myocardium can be observed with compromise due to multiple epithelial, 
non-necrotizing, focal, and coalesced granules, which involve about 30% of the tissue analyzed. The granules 
contain numerous multinucleated giant cells and, in the confluent areas, are associated with interstitial fibrosis. 
Stains were negative for mycobacteria and fungi.
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Another form of presentation of arrhythmia is supraventricular tachycardia. In 
a retrospective study of 100 cases, the global prevalence of these arrhythmias was 
32%, with auricular fibrillation being the most frequently detected arrhythmia; the 
methods used for detection were continuous electrocardiogram, Holter monitoring 
devices, and electrophysiological studies. The majority of patients were asymp-
tomatic (96%), and after atrial fibrillation, in order of frequency, they had atrial 
tachycardia and atrial flutter. The presence of diastolic dysfunction, increase in the 
size of the left atrium, and arterial hypertension were the most important factors in 
the multivariate analysis [10].
Sudden death is a more unusual situation in cardiac sarcoidosis, but when it 
takes place, it is usually subsequent to severe malfunction in atrioventricular con-
duction or ventricular arrhythmia. It seems that the presence of delayed enhance-
ment with gadolinium in nuclear magnetic resonance imaging correlated with this 
outcome; however, these findings are yet to be confirmed.
In some people, cardiac failure can be the main manifestation, followed by dys-
pnea, orthopnea, and lower limb edema [11]. The right or left ventricular function 
may be compromised; there may be disorders of segmental or global contractility, as 
well as valvular compromise, and pulmonary hypertension [12]. There should be a 
high degree of suspicion regarding this condition, principally when there is a mani-
fest extrapulmonary clinical picture or antecedents of such condition are not present.
The involvement of the epicardial coronary arteries is rare; however, there 
are reports of cases of vasculitis presenting as acute coronary syndrome and even 
spontaneous dissection of the coronary arteries, cardiac tamponade, and death in 
patients without any known antecedents of cardiac sarcoidosis [13, 14].
5. Diagnosis
The diagnosis of this condition in particular starts with a high index of suspi-
cion; other possible causes must not be overlooked, taking into consideration the 
wide clinical spectrum of this pathology. The treatment of this condition requires 
a significant medical effort with clinical imaging and, in many cases, histological 
correlation.
Cardiac compromise due to sarcoidosis should be suspected when the following 
conditions take place in which the most frequent causes are excluded [15]:
• Advanced atrioventricular block in patients younger than 60 years old
• Cardiac failure
• Ventricular arrhythmia
In addition, clinical suspicion should be higher in all patients with antecedents 
of extracardiac sarcoidosis that occurred with a cardiovascular symptom such as 
syncope, arrhythmias, or cardiac insufficiency.
Thus, the diagnosis of this pathology starts with clinical suspicion generated 
after a detailed medical record and an exhaustive physical exam of those conditions 
that might explain the current clinical picture is ruled out and identification of 
extracardiac compromise is found to be due to sarcoidosis.
The use of complementary studies should follow a logical sequence that supports 
or rules out the suspicion generated in the clinic. The following complementary 
tests must be performed:
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5.1 Chest image
Chest image continues to be the initial study; it is used to identify the typical 
anomalies of cardiac sarcoidosis; chest images are reported as abnormal in up to 
95% of the cases [16] reserving high-resolution tomography for those cases in which 
the thorax image is normal or presents atypical findings. Image analysis should 
always take into consideration the multiple differential diagnoses, infections, or 
conditions that might compromise the lung in a similar way [17].
5.2 Electrocardiogram and Holter
The electrocardiogram is abnormal in the majority of patients with symptomatic 
cardiac sarcoidosis, compared with patients that have a silent compromise in which 
the abnormality does not go above 9% [4, 18].
In the screening of asymptomatic patients with extracardiac sarcoidosis con-
firmed via biopsy [19], the most suggestive findings are:
• Right or left branch block
• One or more signals of a signal-averaged ECG
• One or more premature ventricular complexes
• Presence of Q wave in two or more adjacent leads in the absence of myocardial 
infarction
• Fragmented QRS in two or more adjacent leads in the absence of myocardial 
infarction
• Atrial arrhythmia (atrial tachycardia or atrial fibrillation)
Table 1 summarizes the ECG manifestations with variable prevalence according 
to the course of the cardiac sarcoidosis [19].
As noted before, up to 34% of cases show malfunction in atrioventricular con-
duction (57% of patients being reversible in some series after immunosuppression 
therapy) [19]. Other alterations identified are changes in the ST T wave and rarely 
epsilon waves [4].
Ambulatory electrocardiographic monitoring which continues for 24–48 h 
(Holter) is useful for identification of arrhythmias, as well as their response to 
treatment [20].
5.3 Echocardiogram
The echocardiographic findings are diverse with low sensitivity and specific-
ity; however, they are useful for follow-up of patients to monitor progression of 
the disease [3]. The alterations that stand out include anomalies of the segmental 
and global contractility (usually following a non-coronary epicardial pattern), 
thickening or thinning of the interventricular septum (especially toward the base), 
diastolic dysfunction, and ventricular hypertrophy which can simulate a hypertro-
phic cardiomyopathy and aneurysms [4]. In recent studies, interest has grown in 
utility of longitudinal deformity of the left ventricle via Speckle-tracking analysis 
to identify patients with cardiac sarcoidosis; this can be a useful tool in the early 
diagnosis and the follow-up of the disease [21].
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5.4 Advanced cardiovascular imaging
5.4.1 Nuclear magnetic resonance imaging
Nuclear magnetic resonance imaging is one of the most useful imaging tech-
niques for the assessment of cardiac sarcoidosis. There is no pattern that can be 
defined as typical; however, the delayed enhancement of the gadolinium is patched 
(and does not follow a vascular pattern); it compromises the myocardium and the 
subepicardium, unlike acute myocardial infraction that compromises the subendo-
cardium; it usually affects the basal segments of the septum and the inferolateral 
wall. Left ventricle involvement is more common. Transmural and right ventricle 
compromise is infrequent; however, these findings do not rule out the presence of 
the cardiac sarcoidosis. Some series report a negative predictive value up to 100% 
with epidemiological limitations with respect to the gold pattern. For this reason, 
although a negative cardiac resonance image is not common, cardiac compromise 
due to this pathology cannot be disregarded, especially if the probability and 
clinical suspicion are high [22, 23]. The superiority of the cardiac nuclear magnetic 
resonance imaging in the diagnosis of sarcoidosis was proven by Ichinose et al. [24]; 
he found sensitivity from 75 to 100% and specificity from 39 to 78%. He showed 
that the NMRI is superior to SPECT with thallium and gallium [25]. The increase 
in the T2 signal correlated in some subjects with inflammation and major adverse 
events; NMRI continues to be studied [20, 22]. The limitations of NMRI include 
patients with implanted cardiac devices (relative), chronic renal disease (stage 4/5), 
and claustrophobia.
5.4.2 Fluorodeoxyglucose positron 18 emission tomography
This imaging technique is useful in cardiac sarcoidosis for the identification of 
possible areas with active inflammatory processes; an algorithm has been proposed 
as a response test to treatment [3]. As a diagnostic guide, a meta-analysis concluded 
89% sensibility and 78% specificity; however, these results should be viewed with 
caution and with the diagnostic criteria used as a pattern [26].
Advanced cardiovascular imaging is advised in the following clinical contexts [27]:
Patients with extracardiac compromise
• Presence of more than one of the following symptoms: 2 weeks + of palpita-
tions, pre-syncope, or syncope
• One or more of the following anomalies in the electrocardiogram: complete 
block of right or left branch, presence of unexplained pathologic Q waves in 
two or more leads, atrioventricular block at any degree of severity, and sus-
tained or non-sustained ventricular tachycardia
Presentation Prevalence (%)
Atrioventricular block 26–67
Bundle block 12–61
Atrial arrhythmias 23–25
Ventricular arrhythmias 11–73
Table 1. 
Prevalence of ECG abnormalities.
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• One or more of the following echocardiographic anomalies: anomalies in the 
regional movement of a wall, ventricular aneurysm, thinning of the interventric-
ular septum (basal segment), and ejection fraction of the left ventricle below 50%
Patients without extracardiac compromise
• Atrioventricular block second-degree Mobitz II or third degree in adults younger 
than 60 years old without an evident cause
• Monomorphic ventricular tachycardia without a clear cause
5.5 Biomarkers
The angiotensin-converting enzyme has been found to be high in 75% of the 
patients with non-treated sarcoidosis, it does not have much diagnostic value due to 
its low sensitivity and specificity, and multiple conditions such as diabetes mellitus, 
tuberculosis, hyperthyroidism, and lung cancer, among other entities, can alter 
its levels [28]. The measurement of the soluble receptor of interleukin 2 has been 
proposed as an inflammatory marker in patients with extrapulmonary disease [28]; 
more studies are needed to assess its use in the clinical setting.
5.6 Endomyocardial biopsy
Being an invasive procedure and considering that sarcoidosis is usually a disease 
with multisystem compromise, it is preferred to identify a possible extracardiac site 
for biopsy and histological studies (lymph nodes or lungs). In cases in which the 
histological tests are not conclusive or there is only cardiac compromise, the endo-
myocardial biopsy becomes important in the diagnosis of this condition. The diag-
nostic performance of a blind biopsy is 25% [29] increasing to 50% when guided by 
images or electroanatomic mapping; this is logical when taking into consideration 
the multifocal nature of the infiltration [30, 31].
6. Diagnostic criteria
There is no global consensus accepted for the diagnosis of cardiac sarcoidosis. 
In 2014 The European Heart Rate Society (HRS) published a consensus for the 
histological and clinical diagnosis of sarcoidosis with cardiac compromise which is 
shown in Table 2 [27].
7. Differential diagnostic
The differential diagnosis of this condition is difficult considering all the 
pathologies that can manifest in a similar form. The complete medical record and 
the physical exam are the most important ways to make a diagnostic approach.
8. Management
The medical and interventional management in sarcoidosis requires interaction 
of a multidisciplinary team that includes a cardiologist, electrophysiologist, rheu-
matologist, pneumologist, and other specialists.
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All patients with cardiac sarcoidosis should have a proper control of cardio-
vascular risk factors, management of cardiac failure in case it occurs, treatment of 
ventricular arrhythmias and atrioventricular conduction malfunction, as well as 
immunosuppression therapy.
Immunosuppression therapy is prescribed in all patients with cardiac sar-
coidosis. The criteria shown in Table 3 should be fulfilled [27]. Corticosteroids 
(prednisolone goes from 30 to 40 mg/day) [32] and the clinical response should 
be assessed 1–3 months after the starting treatment. The dosage should be 
reduced gradually, as low as 5–15 mg/day, until completing 9–12 months of sus-
tained treatment. The patients should undergo clinical follow-up for up to 3 years 
after the therapy to identify relapse. Other therapies (second or third line) 
include methotrexate, infliximab, cyclophosphamide, and azathioprine, used 
in refractory cases or when steroids adverse effects are not tolerated. In immu-
nosuppression treatment it is essential to identify the inflamed myocardium via 
histological study or imaging. It is here where fluorodeoxyglucose positron 18 
emission tomography becomes important. It is worth noting this is proposed as a 
follow-up strategy to define which patients should continue with or discontinue 
therapy [26, 27].
Table 4 lists the recommendations by consensus for the management of 
arrhythmias related to cardiac sarcoidosis [4, 27].
Histological diagnosis of myocardial tissue
Presence of granuloma not classified in the histological exam of the myocardial tissue without an alternative 
identified cause (including staining for microorganisms)
Clinical diagnosis (invasive studies and noninvasive): recognized as probable
a. Histological diagnosis of extracardiac sarcoidosis
b. One or more of the following:
I. Cardiac block or cardiomyopathy with response to immunosuppression therapy with steroids
II. Ejection fraction of the left ventricle reduced in an unexplainable form (<40%)
III. Sustained ventricular tachycardia with no clear cause (spontaneous or induced)
IV. Atrioventricular block second-degree Mobitz II or cardiac block third degree
V. Irregular captation in a positron emission heart tomography (a consistent pattern with cardiac 
sarcoidosis)
VI. Delayed enhancement with gadolinium in a cardiac nuclear magnetic resonance (in a pattern con-
sistent with cardiac sarcoidosis)
VII. Positive gallium captation (in a pattern consistent with cardiac sarcoidosis)
c. Other causes of the cardiac manifestations have been reasonably excluded
Table 2. 
Diagnostic criteria for sarcoidosis (HRS) 2014.
Left ventricular dysfunction and evidence of myocardial inflammation
Cardiac block Mobitz II and degree III and evidence of myocardial inflammation
Sustained ventricular arrhythmia and evidence of myocardial inflammation
Non-sustained ventricular arrhythmia and frequent ventricular ectopy and evidence of myocardial 
inflammation
Table 3. 
Indication of immunosuppression therapy.
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9. Prognosis
In a relatively long series, Tokuda et al. [33] compared behavior and course 
of the cardiac sarcoidosis, after ablation with ventricular tachycardia catheter in 
patients with sarcoidosis and patients with other types of dilated nonischemic 
cardiopathies; 23% of the patients with sarcoidosis had previous arrhythmic storm, 
and 31% had a previous ablation and had been refactored for management with 
two antiarrhythmics. More than 50% had received amiodarone or beta-blockers. 
Although they all shared similar mechanisms of arrhythmogenesis with other 
types of cardiopathies, the group of patients with sarcoidosis had a higher rate of 
recurrence of ventricular tachycardia. After ablation, survival, or rehospitalization 
Management of conduction malfunctions
The implantation of a device can be useful in patients with cardiac sarcoidosis with stimulation 
indication, even if the atrioventricular block is reverted transiently
IIa
Immunosuppression can be useful in patients with cardiac sarcoidosis with atrioventricular block 
second degree (Mobitz II) or third degree
IIa
The implantation of a cardioverter can be useful in patients with cardiac sarcoidosis and an 
indication of permanent implantation of a pacemaker
IIa
Management of ventricular arrhythmias
The assessment of myocardial inflammation via fluorodeoxyglucose positron 18 emission 
tomography can be useful in patients with cardiac sarcoidosis with ventricular arrhythmias
IIa
Immunosuppression can be useful in patients with cardiac sarcoidosis with ventricular arrhythmias 
and evidence of myocardial inflammation
IIa
Therapy via antiarrhythmic medications can be useful in patients with ventricular arrhythmias 
refractory to immunosuppression therapy
IIa
Ablation with catheter can be useful in patients with cardiac sarcoidosis and ventricular 
arrhythmias refractory to immunosuppression and antiarrhythmic therapy
IIa
Indications for implantable cardioverter
Spontaneous sustained ventricular arrhythmias, including previous cardiac arrest I
Ejection fraction of the left ventricle smaller or equal to 35% even with optimal medical 
management and a period of immunosuppression (if there was active inflammation)
I
Implantation of cardioverter can be considered in cardiac sarcoidosis independent from ventricular 
function in one or more of the following:
• Indication of permanent pacemaker implantation
• Unexplained syncope or pre-syncope, if it is of arrhythmic etiology
• Inducible sustained ventricular arrhythmias
IIa
Cardioverter implantation can be considered in patients with ejection fraction from 36 to 49% and/
or ejection fraction of the right ventricle below 40%, even with optimal medical management for 
cardiac failure and a period of immunosuppression (if there was active inflammation).
IIb
Stratification of sudden death risk
An electrophysiological study for the stratification of sudden death can be considered in patients 
with ejection fraction of the left ventricle >35% even with optimal medical management for cardiac 
failure and a period of immunosuppression (if there was active inflammation).
IIb
Cardiac magnetic resonance imaging can be considered for the stratification of sudden death risk. IIb
Table 4. 
Management of conduction malfunctions.
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related to the recurrence of ventricular arrhythmias, was greater in patients with 
cardiac sarcoidosis. This shows that sarcoidosis has the worst prognosis among all 
other forms of nonischemic cardiopathy.
© 2019 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms 
of the Creative Commons Attribution License (http://creativecommons.org/licenses/
by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, 
provided the original work is properly cited. 
10
Sarcoidosis and Granulomatosis - Diagnosis and Management
[1] Okada DR, Bravo PE, Vita T, 
Agarwal V, Osborne MT, Taqueti VR, 
et al. Isolated cardiac sarcoidosis: A 
focused review of an under-recognized 
entity. Journal of Nuclear Cardiology. 
Aug 2018;25(4):1136-1146
[2] Semenzato G. ACCESS: A case 
control etiologic study of sarcoidosis. 
Sarcoidosis, Vasculitis, and Diffuse 
Lung Diseases. 2005;22(2):83-86
[3] Yatsynovich Y, Dittoe N, Petrov M, 
Maroz N. Cardiac sarcoidosis: A review 
of contemporary challenges in 
diagnosis and treatment. The American 
Journal of the Medical Sciences. 
2018;355(2):113-125
[4] Birnie DH, Nery PB, Ha AC, 
Beanlands RS. Cardiac sarcoidosis. 
Journal of the American College of 
Cardiology. 2016;68(4):411-421
[5] Kandolin R, Lehtonen J, Airaksinen J, 
Vihinen T, Miettinen H, Ylitalo K, et al. 
Cardiac sarcoidosis: Epidemiology, 
characteristics, and outcome over 25 
years in a nationwide study. Circulation. 
2015;131(7):624-632
[6] Altamar Jhan A, Carlos T, Diego R, 
Luis S. Ventricular arrhythmias as a 
first sign of primary cardiac sarcoidosis. 
Revista Colombiana de Cardiología. 
2017;24(5):511
[7] Patterson KC, Chen ES. The 
pathogenesis of pulmonary sarcoidosis 
and implications for treatment. Chest. 
2018;153(6):1432-1442
[8] Sakthivel P, Bruder D. Mechanism 
of granuloma formation in sarcoidosis. 
Current Opinion in Hematology. 
2017;24(1):59-65
[9] Nery PB, Beanlands RS, Nair GM, 
Green M, Yang J, McArdle BA, et al. 
Atrioventricular block as the initial 
manifestation of cardiac sarcoidosis 
in middle-aged adults. Journal of 
Cardiovascular Electrophysiology. 
2014;25(8):875-881
[10] Viles-Gonzalez JF, 
Pastori L, Fischer A, Wisnivesky JP, 
Goldman MG, Mehta D. Supraventricular 
arrhythmias in patients with cardiac 
sarcoidosis prevalence, predictors, 
and clinical implications. Chest. 
2013;143(4):1085-1090
[11] Kron J, Ellenbogen KA. Cardiac 
sarcoidosis: Contemporary 
review. Journal of Cardiovascular 
Electrophysiology. 2015;26(1):104-109
[12] Patel MB, Mor-Avi V, Murtagh G, 
Bonham CA, Laffin LJ, Hogarth DK, 
et al. Right heart involvement in patients 
with sarcoidosis. Echocardiography. 
2016;33(5):734-741
[13] Kanaroglou S, Nair V, 
Fernandes JR. Sudden cardiac death 
due to coronary artery dissection 
as a complication of cardiac 
sarcoidosis. Cardiovascular Pathology. 
2015;24(4):244-246
[14] Ward EV, Nazari J, Edelman RR.  
Coronary artery vasculitis as a 
presentation of cardiac sarcoidosis. 
Circulation. 2012;125(6):e344-e346
[15] Soejima K, Yada H. The work-up 
and management of patients with 
apparent or subclinical cardiac 
sarcoidosis: With emphasis on 
the associated heart rhythm 
abnormalities. Journal of 
Cardiovascular Electrophysiology. 
2009;20(5):578-583
[16] Keijsers RG, Veltkamp M, 
Grutters JC. Chest imaging. Clinics in 
Chest Medicine. 2015;36(4):603-619
[17] Ganeshan D, Menias CO,  
Lubner MG, Pickhardt PJ, 
Sandrasegaran K, Bhalla S. Sarcoidosis 
References
11
Cardiac Sarcoidosis
DOI: http://dx.doi.org/10.5772/intechopen.85310
from head to toe: What the radiologist 
needs to know. Radiographics. 
2018;38(4):1180-1200
[18] Hamzeh N, Steckman DA, 
Sauer WH, Judson MA. Pathophysiology 
and clinical management of cardiac 
sarcoidosis. Nature Reviews. Cardiology. 
2015;12(5):278-288
[19] Zipse MM, Sauer WH. 
Electrophysiologic manifestations 
of cardiac sarcoidosis. Current 
Opinion in Pulmonary Medicine. 
2013;19(5):485-492
[20] Freeman AM, Curran-Everett D,  
Weinberger HD, Fenster BE,  
Buckner JK, Gottschall EB, et al. 
Predictors of cardiac sarcoidosis using 
commonly available cardiac studies. 
The American Journal of Cardiology. 
2013;112(2):280-285
[21] Pizarro C, Kluenker F, 
Hammerstingl C, Skowasch D. Diagnostic 
value of speckle-tracking 
echocardiography in confirmed cardiac 
sarcoidosis. Clinical Research in 
Cardiology. 2016;105(10):884-886
[22] Vignaux O, Dhote R, Duboc D, 
Blanche P, Dusser D, Weber S, et al. 
Clinical significance of myocardial 
magnetic resonance abnormalities 
in patients with sarcoidosis: A 
1-year follow-up study. Chest. 
2002;122(6):1895-1901
[23] Smedema JP, Snoep G,  
van Kroonenburgh MP, van 
Geuns RJ, Dassen WR, Gorgels AP, 
et al. Evaluation of the accuracy of 
gadolinium-enhanced cardiovascular 
magnetic resonance in the diagnosis 
of cardiac sarcoidosis. Journal of the 
American College of Cardiology. 
2005;45(10):1683-1690
[24] Ichinose A, Otani H, Oikawa M, 
Takase K, Saito H, Shimokawa H, 
et al. MRI of cardiac sarcoidosis: Basal 
and subepicardial localization of 
myocardial lesions and their effect on 
left ventricular function. AJR. American 
Journal of Roentgenology. 
2008;191(3):862-869
[25] Tadamura E, Yamamuro M, Kubo S, 
Kanao S, Hosokawa R, Kimura T, et al. 
Images in cardiovascular medicine. 
Multimodality imaging of cardiac 
sarcoidosis before and after 
steroid therapy. Circulation. 
2006;113(20):e771-e773
[26] Youssef G, Leung E, Mylonas I, 
Nery P, Williams K, Wisenberg G, et al. 
The use of 18F-FDG PET in the 
diagnosis of cardiac sarcoidosis: A 
systematic review and meta analysis 
including the Ontario experience. 
Journal of Nuclear Medicine. 
2012;53(2):241-248
[27] Birnie DH, Sauer WH, Bogun F, 
Cooper JM, Culver DA, Duvernoy CS, 
et al. HRS expert consensus statement 
on the diagnosis and management 
of arrhythmias associated with 
cardiac sarcoidosis. Heart Rhythm. 
2014;11(7):1305-1323
[28] Gungor S, Ozseker F, Yalcinsoy M, 
Akkaya E, Can G, Eroglu H, et al. 
Conventional markers in determination 
of activity of sarcoidosis. 
International Immunopharmacology. 
2015;25(1):174-179
[29] Bennett MK, Gilotra NA,  
Harrington C, Rao S, Dunn JM, 
Freitag TB, et al. Evaluation of the 
role of endomyocardial biopsy in 851 
patients with unexplained heart failure 
from 2000-2009. Circulation. Heart 
Failure. 2013;6(4):676-684
[30] Liang JJ, Hebl VB, DeSimone CV, 
Madhavan M, Nanda S, Kapa S, et al. 
Electrogram guidance: A method to 
increase the precision and diagnostic 
yield of endomyocardial biopsy for 
suspected cardiac sarcoidosis and 
myocarditis. JACC: Heart Failure. 
2014;2(5):466-473
Sarcoidosis and Granulomatosis - Diagnosis and Management
12
[31] Vaidya VR, Abudan AA, 
Vasudevan K, Shantha G, Cooper LT, 
Kapa S, et al. The efficacy and safety 
of electroanatomic mapping-guided 
endomyocardial biopsy: A systematic 
review. Journal of Interventional 
Cardiac Electrophysiology. 2018
[32] Yazaki Y, Isobe M, Hiroe M, 
Morimoto S, Hiramitsu S, Nakano T, 
et al. Prognostic determinants of long-
term survival in Japanese patients 
with cardiac sarcoidosis treated with 
prednisone. The American Journal of 
Cardiology. 2001;88(9):1006-1010
[33] Tokuda M, Tedrow UB, Kojodjojo P, 
Inada K, Koplan BA, Michaud GF, et al. 
Catheter ablation of ventricular 
tachycardia in nonischemic heart 
disease. Circulation. Arrhythmia and 
Electrophysiology. 2012;5(5):992-1000
